Literature DB >> 29383513

A common CHRNE mutation in Brazilian patients with congenital myasthenic syndrome.

Eduardo de Paula Estephan1, Cláudia Ferreira da Rosa Sobreira2, André Clériston José Dos Santos2, Pedro José Tomaselli2, Wilson Marques2, Roberta Paiva Magalhães Ortega3, Marcela Câmara Machado Costa4, André Macedo Serafim da Silva1, Rodrigo Holanda Mendonça1, Vitor Marques Caldas1, Antonio Alberto Zambon1, Osório Abath Neto1, Paulo Eurípedes Marchiori1, Carlos Otto Heise1, Umbertina Conti Reed1, Yoshiteru Azuma5, Ana Töpf5, Hanns Lochmüller5, Edmar Zanoteli6.   

Abstract

The most common causes of congenital myasthenic syndromes (CMS) are CHRNE mutations, and some pathogenic allelic variants in this gene are especially frequent in certain ethnic groups. In the southern region of Brazil, a study found the c.130dupG CHRNE mutation in up to 33% of families with CMS. Here, we aimed to verify the frequency of this mutation among individuals with CMS in a larger cohort of CMS patients from different areas of Brazil and to characterize clinical features of these patients. Eighty-four patients with CMS, from 72 families, were clinically evaluated and submitted to direct sequencing of the exon 2 of CHRNE. The c.130dupG mutation was found in 32 patients (23 families), with 26 patients (19 families, 26.3%) in homozygosis, confirming its high prevalence in different regions of Brazil. Among the homozygous patients, the following characteristics were frequent: onset of symptoms before 2 years of age (92.3%), little functional restriction (92.3%), fluctuating symptoms (100%), ocular muscle impairment (96.1%), ptosis (100%), limb weakness (88.4%), response to pyridostigmine (100%), facial involvement (77%), and bulbar symptoms (70.8%). The pretest probability of finding at least one allele harbouring the c.130dupG mutation was 38.1%. Selecting only patients with impaired eye movement together with limb weakness and improvement with pyridostigmine, the probability increases to 72.2%. This clinical pre-selection of patients is likely a useful tool for regions where CHRNE mutations have a founder effect. In conclusion, the CHRNE mutation c.130dupG leads to fairly benign natural course of the disease with relative homogeneity.

Entities:  

Keywords:  Acetylcholine receptor; CHRNE; Congenital myasthenic syndrome; Neuromuscular junction; Pyridostigmine

Mesh:

Substances:

Year:  2018        PMID: 29383513      PMCID: PMC7115868          DOI: 10.1007/s00415-018-8736-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  19 in total

1.  Myasthenia gravis in a woman with congenital AChR deficiency due to epsilon-subunit mutations.

Authors:  Rebecca Croxen; Angela Vincent; John Newsom-Davis; David Beeson
Journal:  Neurology       Date:  2002-05-28       Impact factor: 9.910

Review 2.  Congenital myasthenic syndromes: an update.

Authors:  Sarah Finlayson; David Beeson; Jacqueline Palace
Journal:  Pract Neurol       Date:  2013-04

3.  Nonlethal CHRNA1-Related Congenital Myasthenic Syndrome with a Homozygous Null Mutation.

Authors:  Osorio Abath Neto; Carlos Otto Heise; Cristiane de Araújo Martins Moreno; Eduardo de Paula Estephan; Lilia Mesrob; Doris Lechner; Anne Boland; Jean-François Deleuze; Acary Souza Bulle Oliveira; Umbertina Conti Reed; Valérie Biancalana; Jocelyn Laporte; Edmar Zanoteli
Journal:  Can J Neurol Sci       Date:  2016-10-17       Impact factor: 2.104

4.  Molecular characterisation of congenital myasthenic syndromes in Southern Brazil.

Authors:  V Mihaylova; R H Scola; B Gervini; P J Lorenzoni; C K Kay; L C Werneck; R Stucka; V Guergueltcheva; M von der Hagen; A Huebner; A Abicht; J S Müller; H Lochmüller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-06-20       Impact factor: 10.154

Review 5.  Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment.

Authors:  Andrew G Engel; Xin-Ming Shen; Duygu Selcen; Steven M Sine
Journal:  Lancet Neurol       Date:  2015-04       Impact factor: 44.182

6.  Congenital myasthenic syndrome (CMS) in three European kinships due to a novel splice mutation (IVS7 - 2 A/G) in the epsilon acetylcholine receptor (AChR) subunit gene.

Authors:  N Barisic; C Schmidt; O P Sidorova; A Herczegfalvi; B M Gekht; I-H Song; R Stucka; V Karcagi; A Abicht; H Lochmüller
Journal:  Neuropediatrics       Date:  2002-10       Impact factor: 1.947

7.  Myasthenic syndromes in Turkish kinships due to mutations in the acetylcholine receptor.

Authors:  K Ohno; B Anlar; E Ozdirim; J M Brengman; J L DeBleecker; A G Engel
Journal:  Ann Neurol       Date:  1998-08       Impact factor: 10.422

8.  Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes.

Authors:  Violeta Mihaylova; Juliane S Müller; Juan J Vilchez; Mustafa A Salih; Mohammad M Kabiraj; Adele D'Amico; Enrico Bertini; Joachim Wölfle; Felix Schreiner; Gerhard Kurlemann; Vedrana Milic Rasic; Dana Siskova; Jaume Colomer; Agnes Herczegfalvi; Katarina Fabriciova; Bernhard Weschke; Rosana Scola; Friederike Hoellen; Ulrike Schara; Angela Abicht; Hanns Lochmüller
Journal:  Brain       Date:  2008-01-07       Impact factor: 13.501

9.  Molecular characterization of congenital myasthenic syndromes in Spain.

Authors:  D Natera-de Benito; A Töpf; J J Vilchez; L González-Quereda; J Domínguez-Carral; J Díaz-Manera; C Ortez; M Bestué; P Gallano; M Dusl; A Abicht; J S Müller; J Senderek; A García-Ribes; N Muelas; T Evangelista; Y Azuma; G McMacken; A Paipa Merchan; P M Rodríguez Cruz; A Camacho; E Jiménez; M C Miranda-Herrero; A Santana-Artiles; O García-Campos; R Dominguez-Rubio; M Olivé; J Colomer; D Beeson; H Lochmüller; A Nascimento
Journal:  Neuromuscul Disord       Date:  2017-08-18       Impact factor: 4.296

10.  Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes.

Authors:  Pedro M Rodríguez Cruz; Jacqueline Palace; Hayley Ramjattan; Sandeep Jayawant; Stephanie A Robb; David Beeson
Journal:  Neurology       Date:  2015-09-22       Impact factor: 9.910

View more
  1 in total

1.  Targeted therapies for congenital myasthenic syndromes: systematic review and steps towards a treatabolome.

Authors:  Rachel Thompson; Gisèle Bonne; Paolo Missier; Hanns Lochmüller
Journal:  Emerg Top Life Sci       Date:  2019-01-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.